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Background: A33 is a type II integral membrane protein expressed on the extracellular enveloped form of vaccinia
virus (VACV). Passive transfer of A33-directed monoclonal antibodies or vaccination with an A33 subunit vaccine
confers protection against lethal poxvirus challenge in animal models. Homologs of A33 are highly conserved
among members of the Orthopoxvirus genus and are potential candidates for inclusion in vaccines or assays
targeting extracellular enveloped virus activity. One monoclonal antibody directed against VACV A33, MAb-1G10,
has been shown to target a conformation-dependent epitope. Interestingly, while it recognizes VACV A33 as well as
the corresponding variola homolog, it does not bind to the monkeypox homolog. In this study, we utilized a
random phage display library to investigate the epitope recognized by MAb-1G10 that is critical for facilitating
cell-to-cell spread of the vaccinia virus.
Results: By screening with linear or conformational random phage libraries, we found that phages binding to
MAb-1G10 display the consensus motif CEPLC, with a disulfide bond formed between two cysteine residues
required for MAb-1G10 binding. Although the phage motif contained no linear sequences homologous to VACV
A33, structure modeling and analysis suggested that residue D115 is important to form the minimal epitope core. A
panel of point mutants expressing the ectodomain of A33 protein was generated and analyzed by either binding
assays such as ELISA and immunoprecipitation or a functional assessment by blocking MAb-1G10 mediated comet
inhibition in cell culture.
Conclusions: These results confirm L118 as a component of the MAb-1G10 binding epitope, and further identify
D115 as an essential residue. By defining the minimum conformational structure, as well as the conformational
arrangement of a short peptide sequence recognized by MAb-1G10, these results introduce the possibility of
designing small molecule mimetics that may interfere with the function of A33 in vivo. This information will also be
useful for designing improved assays to evaluate the potency of monoclonal and polyclonal products that target
A33 or A33-modulated EV dissemination.
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Despite the eradication of naturally occurring smallpox,
the licensed smallpox vaccine is still administered to
military personnel and first responders due to the threat
of bioterrorism [1], as well as to individuals with poten-
tial exposure to monkeypox. In February 2008, the Cen-
ters for Diseases Control and Prevention (CDC)
disposed of the last of its 12 million doses of Dryvax, the
licensed first generation smallpox vaccine grown on the
skin of calves. A new vaccine, ACAM2000, was licensed
by the Food and Drug Administration in 2007 as a re-
placement. ACAM2000 is a replication-competent vac-
cinia virus clone derived from Dryvax and manufactured
in large scale mammalian cell cultures. Efficacy was
determined in a number of animal models and found to
be non-inferior to Dryvax in eliciting an immunological
response; however ACAM2000 has a similar safety pro-
file when compared to Dryvax and introduces a level of
risk for a small subset of individuals [2]. These compli-
cations may be severe and life-threatening. Severe ad-
verse events following vaccination may include eczema
vaccinatum (EV) in patients with atopic dermatitis and
certain other skin conditions, and progressive vaccinia
(PV) in immunocompromised patients [3-6].
Vaccinia Immune Globulin Intravenous (Human)
(VIGIV), a polyclonal antibody preparation manufactu-
red from plasma of vaccinia-immunized donors, is the
only licensed therapy for smallpox vaccine complica-
tions. While no placebo-controlled clinical trials were
performed with the currently available VIGIV product,
the use of similar products has historically decreased
mortality, from 100% to 50% for PV, and from 30-40% to
3-4% for EV (reviewed in [7]). In severe cases very high
repeated doses of VIGIV have been used and in the con-
text of widespread vaccination, VIGIV supply could be
limiting [6,8]. Enhancing the potency of licensed VIGIV
is challenging in part because virus neutralizing assays
for screening donor plasma are laborious, require live
virus, and are subject to the variability typically encoun-
tered in biological assays. Binding assays to quantitate
antibody levels are problematic in the absence of spe-
cific epitope binding information or in the context of
polyclonal preparations that may contain a mixture of
neutralizing and non-neutralizing antibodies, and are
therefore typically supported by use of a plaque reduc-
tion neutralization assay [9]. Since immunogenicity is a
critical consideration in vaccine development, structural
understanding of critical viral protein epitopes would aid
development of feasible assays capable of measuring
important antibody specificities in donor plasma and
VIGIV.
During the poxvirus infectious life cycle, approxi-
mately 1% of intracellular mature virions (IMV) are
wrapped with additional membrane and exocytosed asextracellular enveloped virus (EEV) (reviewed in [10]).
While IMV may mediate host-to-host transmission
[11,12], EEV are thought to be uniquely responsible for
rapid spread of virus in vivo and present an important
antibody target. Antibody-mediated inhibition of EEV
release from infected cells and blockade of EEV entry
have been demonstrated [13-15]. Passive immunization
is more effective in polyclonal antibody preparations
containing higher EEV antibody titers [16], and anti-EEV
monoclonals provide protection in a mouse vaccinia
intranasal challenge model [17]. Vaccination with EEV
proteins can also elicit a protective immune response
[18]. Unfortunately, in immunized individuals anti-EEV
titers vary considerably and may decline over time post-
vaccination [19,20]. Anti-EEV antibody levels are also va-
riable among different VIG products (M. Kennedy and
R. Fisher, unpublished data) suggesting that potency
gains might be realized by selecting plasma of donors
with more robust responses to EEV neutralizing surface
determinants. However, identification and characteriza-
tion of EEV neutralizing determinants is still incomplete
and assays to measure EEV neutralizing activity are sub-
ject to a high degree of variability.
The EEV envelope contains several viral proteins, in-
cluding A56R [21,22], F13L [23,24], B5R [13,25], A36R
[26], A34R [27,28], and A33R [29]. Among those, B5
[30] and A33 [31] proteins are known neutralization or
viral spread inhibition targets associated with the EEV
membrane and/or infected cells. The A33 protein ap-
pears to regulate EEV egress from cells and interacts
with A36 to antagonize superinfection of neighboring
cells, promoting more rapid long-distance dissemination
[32-34]. Antibodies such as MAb-1G10 directed against
A33 block comet formation in vitro and can protect
against poxvirus challenge in vivo in passive transfer
models [31,35-37].
MAb-1G10 was initially characterized as an A33-
binding monoclonal antibody that could provide partial
protection in vivo against an intranasal VACV-WR chal-
lenge in a mouse model, as well as block EV spread in
cell culture [37]. Although a disconnect between pro-
tective efficacy and antibody affinity has been demon-
strated for antibodies raised against A33 [35], A33 has
been evaluated as part of an effort to identify epitopes
which might be cross-protective against multiple patho-
genic poxviruses [38]. This analysis showed that the
β-mercaptoethanol sensitive MAb-1G10 epitope on vac-
cinia A33 was not present in the monkeypox A33 ortho-
log A35; the interpretation was that the MAb-1G10
binding epitope was conformational in nature. Binding
of MAb-1G10 to the monkeypox A35 protein could be
restored by single-residue exchanges at positions 117,
118, and 120 changing the monkeypox sequence to the
vaccinia sequence. Based on this information, residues
Figure 1 Amino acid sequence alignment of orthopoxvirus A33
homologs. D115 is conserved across species, while residues 118
and 120 demonstrate heterogeneity.
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MAb-1G10 epitope. The importance of this region was
reinforced by crystallographic data from a fragment of
the ectodomain of A33 (residues 98–185) [39]. A di-
meric, β-strand rich structural model of vaccinia A33
with structural similarity with C-type lectins was pro-
posed. The described structure featured 5 β-strands and
2 α-helices stabilized by 2 intramolecular disulfide bonds
(C100-C109 and C126-C180). Residues 117–120 were
mapped to a surface-exposed edge on the proposed mo-
nomer structure, well removed from the dimer and pro-
posed ligand-binding interfaces.
To provide additional characterization of the epitope
involved in cell to cell spread of vaccinia, we considered
whether additional residues might influence MAb-1G10
binding in the context of the vaccinia A33 protein. In
this study, we screened a random peptide phage display
library to find peptides specifically bound by MAb-
1G10. A conformationally constrained consensus motif
of seven residues was analyzed against available A33 se-
quence and structural information to generate an epi-
tope model, which was tested and confirmed by an
alanine site directed mutagenesis approach. The results
demonstrated that the negatively charged D115 is
required for MAb-1G10 binding, and helps establish the
minimum epitope core for MAb-1G10 binding in the in-
tact vaccinia A33 protein. Our data also confirm that
residue L118 contributes to epitope formation, in agree-
ment with previous observations. Our study shows that
an unbiased mapping strategy utilizing random peptide
display technology can effectively map linear and con-
formational epitopes involved in facilitating cell to cell
spread of vaccinia. This work also expands understand-
ing of an important orthopoxvirus epitope, which may
be exploited to improve and inform therapies for vac-
cinia and potentially smallpox.
Results
Screening of random peptide libraries
In considering the aligned sequences of poxvirus A33
homologs (Figure 1), we noted more subtle patterns of
alternating highly-charged residues and hydrophobic
stretches, and the striking heterogeneity of charged resi-
dues in the proposed region of the MAb-1G10 epitope.
If non-convalent interactions among charged and hydro-
phobic residues influence regional conformation, then
the context of the MAb-1G10 epitope (for example,
presentation of the epitope in a monkeypox A35 versus
vaccinia A33 backbone) might yield different epitope
mapping information. On this basis we decided to
pursue additional characterization of the MAb-1G10
epitope. To obtain unbiased information on the confor-
mationally distinct epitope interacting with MAb-1G10,
a disulfide-constrained heptapeptide library screeningapproach was used. In this approach, the randomized
peptide segment is flanked by paired cysteines, which
are oxidized during phage assembly to present the pep-
tide as a taut loop at the N-terminus of the minor phage
coat protein PIII. Ten MAb-1G10 binding peptides
were isolated from the conformational library scree-
ning, none of which contain vaccinia virus A33 sequence
(Figure 2A). Two consensus motifs were identified:
CXXY(F)NEPL(F)C, and CXXXWPF(H)EC. Biotinylated
peptide mimics were subsequently constructed to verify
MAb-1G10 binding in a solid-phase assay (Figure 2B).
Strong interaction of MAb-1G10 with one of the pep-
tides (RF2-1), containing the CXXY(F)NEPL(F)C motif,
was confirmed in the ELISA based assay (Figure 3A). We
observed that N-ethylmaleimide treatment of reduced
peptide RF2-1 blocked MAb-1G10 binding (Figure 3B),
suggesting that intact disulfide bonds were important for
epitope conformation. A second pass of library screening
was undertaken to determine if additional consensus
motifs might be obtained. The second screen utilized a
phage library in which linear dodecapeptides were pre-
sented at the N-terminus of phage coat protein PIII. Two
MAb-1G10 binding peptides were obtained by screening
the linear peptide library, neither of which contained viral
sequence and both containing a consensus CEPLC motif
(Figure 2A). A comparison of peptide sequences obtained
from the 2 library screens suggested that the conforma-
tionally constrained CEPLC sequence was likely to be
functionally identical to the minimal core MAb-1G10
epitope.
Molecular modeling of the MAb-1G10 epitope
While the CELPC sequence is not present in vaccinia
A33, we reasoned that the conformation of the con-
strained CELPC motif might be identifiable in the folded
A33 protein. A molecular model of the short consensus
CELPC peptide was constructed (Figure 4A) as an aid in
identifying potential MAb-1G10 binding regions in the
intact A33 molecule. For this, the molecular coordinates
Figure 2 Epitope mapping of MAb-1G10. (A) Results of phage
display screening against MAb-1G10 using a 7-mer (C7C;
conformatially constrained by inclusion of flanking cysteines) and a
linear (no conformational constraints) 12-mer library. Phage vector
sequences are indicated by bold type. (B) Chemically synthesized
epitope peptides containing Cluster I and Cluster II consensus
sequences. Conserved residues are underlined.
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(181)) and without (pdbid 1M6B, C(304)GGLC(308)) di-
sulphide bonds were extracted. Although both structures
are loops, the presence or absence of the disulphide
bond prescribes a different topology for these sequences.
To better visualize the difference, we “mutated” the
CGGLC sequence in silico to the phage consensus se-
quence (CEPLC) using Pymol and subsequently under-
took energy minimization of this model for 5000 steps
in vacuum using CHARMM field. The resulting model
showed the disulfide bonded CEPLC peptide featuring
an 11.7 angstrom distance between the charged glutam-
ate side chain and the hydrophobic leucine residue,
whereas in the reduced loop the similar distance (aspar-
tate-leucine) was only 6.9 angstroms. If this model was
accurate, two outcomes were possible. First, reducingthe disulphide bond would reduce the binding of the
phage peptide to MAb-1G10 antibody by virtue of alter-
ing the conformation of the loop and second, and most
importantly, the mature A33 molecule must contain in
its surface residues similar to E and L at a similar rela-
tive position as the consensus phage peptide. Probing
the published structure of A33 for a surface-exposed re-
gion with a distance between charged and hydrophobic
residues similar to the CEPLC peptide yielded a possible
match at residues D115 and L118 (Figure 4B), which are
separated by 11.4 angstroms in the structure model of
the A33 protein [39]. However, given the results from
heptapeptide phage display, we could not rule out an al-
ternative possibility that more complex interactions
among D115, Y178, and N125 might influence the shape
of the MAb-1G10 epitope by long range hydrogen bond-
ing interactions (Figure 4C).
Confirmation of critical MAb-1G10 residues by alanine
scanning
An alanine scanning technique was used to determine if
either of these hypotheses regarding the MAb-1G10 epi-
tope structure might be correct. To accomplish this, the
ectodomain of wild type A33 (residues 59–186) was
expressed in E. coli as a His-tagged recombinant protein,
isolated from inclusion bodies, and refolded on an affin-
ity purification column. To confirm the process of pro-
tein refolding, the native, soluble A33 protein was also
generated from E. coli cytosolic fractions for comparative
purposes. Binding to MAb-1G10 was found comparable
by ELISA and immunoprecipitation (Figure 5A and B),
as well as to another anti-A33 MAb 10F10 by ELISA
[38]. Since protein recovery yields were much higher for
the proteins isolated from inclusion bodies, we chose to
utilize refolded recombinant proteins for further
characterization. We used site directed mutagenesis to
prepare a series of A33 variants in which alanine resi-
dues were individually substituted for D115, Y116,
Q117, L118, N125, and E129. In addition, a series of
double alanine substitution A33 variants and a quadru-
ple alanine substitution A33 variant were constructed.
All of these were successfully expressed in E. coli with
similar efficiency and purity as compared to E. coli
expressed wild type recombinant A33 (rA33; Supple-
mental Figure 2). MAb-1G10 binding was disrupted by
mutations at positions 115 or 118, suggesting that these
residues are critical in the MAb-1G10 epitope. In con-
trast, alanine substitutions at residues 116, 117, 120, 125,
and 129 did not prevent interaction with MAb-1G10.
Confirming the MAb-1G10 epitope using an in vitro
functional test
Inhibition of EEV spread can be functionally evaluated
in vitro using an established method in which EEVs
Figure 3 MAb-1G10 binding to chemically synthesized peptides containing Cluster I and Cluster II consensus sequences. (A) Peptides
RF2-1 and RF2-5 demonstrate increased binding to MAb-1G10 when compared to an unrelated control antibody. (B) Treatment of reduced
peptide RF2-1 with N-ethylmaleimide (NEM) significantly reduces MAb-1G10 binding compared to treatment with PBS alone (control), indicating
the requirement for a conformational structure constrained by a disulphide bond. Binding levels were compared using Student’s t-test.
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ques, commonly referred to as the comet assay. Addition
of MAb-1G10 to the supernatant following adsorption
of virus to target cells blocked the development of satel-
lite plaques in a dose-dependent manner, with most
comets blocked at 12.5 μg/ml (Figure 6). To demon-
strate functional relevance of our assays, we tested the
ability of our phage and recombinant protein prepara-
tions to interfere with the comet neutralizing capacity of
MAb-1G10. When phage expressing the CELPC consen-
sus motif (Figure 6) were included in the comet assay
along with MAb-1G10 , satellite plaques were restored,
demonstrating that MAb-1G10 activity had been abol-
ished. Conversely, when A33 variant proteins containing
D115A or L118A mutations were added to the comet
assay along with MAb-1G10 , there was no effect on
MAb-1G10 comet-neutralizing activity, confirming the
loss of a functional MAb-1G10 epitope in these A33
mutant proteins (Figure 7). Addition of Y116A orFigure 4 Modeling of proposed MAb-1G10 binding structures. (A) Mo
disulphide bond is depicted in yellow, oxygen and nitrogen atoms are colo
structure using coordinates from [PDB: 3K7B] [39]. The strand-loop-helix reg
(see text) is shown. Leucine and aspartate side chains are depicted in stick
Alternative conformational epitope also consistent with phage display data
involved; mutational analysis did not support this hypothesis. Distances ~3Q117A variant A33 proteins had no effect on MAb-
1G10 activity in the comet assay (data not shown). Inter-
estingly, A33 containing a S120A mutation retained
some ability to interact with 1G10 (Figure 7).Discussion
We used a randomized peptide library screen to evaluate
the A33 comet inhibiting epitope recognized by mono-
clonal antibody MAb-1G10. Phage technology offers the
opportunity to explore the interactive determinants of
proteins without preexisting assumptions about the con-
text of the interactions. In this case, the conformation-
ally constrained peptide sequence identified in our
library screening was successfully matched with a puta-
tive surface-exposed region of vaccinia A33 previously
implicated in MAb-1G10 binding. However, our analysis
implicated a new upstream residue, D115, in MAb-1G10
binding. As this residue is completely conserved amongdel of the phage display peptide CEPLC in stick representation;
red red and blue respectively. (B) Cartoon representations of the A33
ion of the A33 protein similar to the phage display peptide CEPLC
representation and the distance between them displayed. (C)
where long-range interactions between A33 residues could be
Å between polar groups are shown in broken lines.
Figure 5 Binding assays evaluating rA33 proteins containing alanine residues at the specified location(s). (A) rA33 proteins were used in
an ELISA format assay to capture MAb-1G10 and were (B) tested for their ability to bind MAb-1G10 in an immunoprecipitation assay.
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1G10 binding was not considered in previous studies.
Blocking in vivo dissemination of vaccinia virus is an
important approach to controlling complications of vac-
cination in at risk individuals. Poxvirus spread within
the host is accelerated by the double-enveloped EEV,
which are propelled by actin tails and released prior toFigure 6 MAb-1G10 binding phage can interfere with 1G10’s ability t
12.5 μg/mL MAb-1G10 1 hour post infection, and either control phage or p
1 × 1011 pfu/mL, or 1 × 1010 pfu/mL. The monolayers were fixed and stainedtarget cell lysis [40]. A33 is one of the proteins presented
on the EEV surface [41] and deletion of the A33R gene
in vaccinia virus reduces disease in an experimental in-
fection model due to inefficient cell-to-cell spread [34].
A33 has also been shown to interact through its cyto-
plasmic and transmembrane regions with A36 [42], and
these EEV proteins together may enhance long-rangeo block EEV-mediated virus spread. Wells labeled ‘MAb+’ received
hage expressing the RF2-1 consensus sequence at 1 × 1012 pfu/mL,
46 hours post infection.
Figure 7 rA33 proteins containing substitutions at D115 or L118 do not interfere with MAb-1G10’s ability to block EEV-mediated virus
spread. Duplicate wells labeled ‘MAb+’ received 12.5 μg/mL MAb-1G10 1 hour post infection, and a 10-fold molar excess of the indicated rA33
proteins. The monolayers were fixed and stained 46 hours post infection.
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by cells [32]. Vaccine-induced or passively transferred
anti-A33 antibodies can mediate protection against le-
thal orthopoxvirus disease in animal models [31,35-37].
Because A33 is a critical component of vaccinia viru-
lence, neutralizing strategies which target this protein
may be particularly effective and thus require appropri-
ate potency assays.
Anti-EEV antibody responses are without exception
important for prophylaxis and treatment of poxviruses
in animal models. However, serological assessment of
anti-EEV antibodies in human smallpox vaccine studies
or as a component of passive antibody therapy has been
limited. In part this is due to use of well-established
PRNT assays, which measure anti-IMV but not anti-EEV
activity. Measuring EEV activity has proven challenging
due to the fragile nature of the viral envelope [41] and
the infectious nature of both EEV and IMV forms of the
virus. The comet inhibition assay for EEV antibodies is
useful for research studies, but is difficult to validate,
and does not provide a robust quantititative result.
The importance of measuring anti-EEV antibodies is
underscored by observations that anti-B5 and anti-A33
antibody levels are variable in polyclonal VIGIV prepara-
tions using research tests (Fisher and Kennedy, unpub-
lished). Binding assays such as ELISAs offer several
advantages in terms of reproducibility, speed, and ro-
bustness; however to be truly predictive of potency the
assay should be specific for a known neutralizing epitope
(or epitopes). The current study provides thorough
characterization of an A33 conformational comet inhi-
biting epitope and links the epitope to a viral spread
assay. Peptide mimics reflecting the MAb-1G10 binding
epitope can be tested in a robust solid phase assay for-
mat. Further development and optimization of an assay
for evaluation of VIGIV products is currently underway.
Additionally, such methods could be used to efficient-
ly screen plasma of vaccinated donors for inclusion
in plasma pools used to manufacture VIGIV, or forconvalescent plasma intended for therapy in the event of
a smallpox outbreak.
To be comprehensive, an optimal anti-EEV assay
should include more than one EEV epitope for assess-
ment unless presence of 1G10-like antibodies is shown to
be a more general marker for robust anti-EEV responses.
A limitation to this broader approach is lack of detailed
structural information for other important target EEV
proteins such as B5. In the absence of such data, valid-
ation of peptides identified in a random display approach
is more challenging. Another consideration is accurately
reflecting or providing a correlation to effector mechan-
isms such as complement or Fc receptor involvement
[17,43]. Our future studies will include structural analysis
of key vaccinia-neutralizing targets to support random
peptide library screening efforts, as well as evaluating
neutralizing epitope/effector mechanism interactions.
The risks of serious side effects from current live atte-
nuated vaccinia virus vaccines provide the impetus for
renewed efforts to develop safer and effective alterna-
tives. So far approaches to develop safe smallpox vac-
cines have ranged from the study of highly attenuated
live vaccinia viruses [44-46] to use of alphavirus replicon
vectors expressing vaccinia genes [47] to subunit vac-
cines delivered either as DNA plasmids [31,48] or puri-
fied proteins [49,50]. An alternative approach to vaccine
design is the use of molecules that mimic the immuno-
genic element of interest. For example, peptide mimics
coupled with carrier proteins or presented as polymers
have been developed for cancer, anti-allergic and contra-
ceptive vaccines [51,52]. Interestingly, peptide mimics
need not have similarity to any linear sequence of the
antigen but rely on the use of conformation dependent
epitopes to stimulate antibodies that will cross-react
with the target antigen.
Conclusions
These results confirm L118 as a component of the
MAb-1G10 binding epitope, and further identify D115
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formational structure, as well as the conformational ar-
rangement of a short peptide sequence recognized by
MAb-1G10, these results introduce the possibility of
designing small molecule mimics that may interfere with
the function of A33 in vivo. Our current study demon-
strates how an interdisciplinary approach integrating
conformational peptide display, structure mapping, and
a biologically relevant assay provides a more complete
characterization of an important vaccinia epitope. Our
findings suggest an additional option for vaccine subunit
development, the possibility of using streamlined assays
to assess anti-EEV vaccine responses, and provide a path
towards improved potency evaluation of passive immune
therapies for human orthopoxvirus disease.
Methods and materials
Virus stocks, antibodies and cells
The IHDJ strain of vaccinia virus was obtained from
the laboratory of Bernard Moss (NIAID) and passaged
once through Vero E6 cells (ATCC). Vero E6 cells were
maintained in cDMEM (Dubelco’s minimal essential
media containing 10% fetal bovine serum, 4.5 mg/mL
D-glucose, 110 μg/mL sodium pyruvate, 100 μM nones-
sential amino acids, 100 U/mL penicillin/streptomycin,
and 0.25 μg/mL amphotericin) and infected at a low
MOI (0.2) for 1 hour at 37°C, and were then incubated
at 37°C and monitored for cytopathic effect daily. On
day 3 postinfection, cells and cell culture supernatant
were removed to centrifuge tubes and spun for 15 min-
utes at 2000 × g at 4°C in an Eppendorf Model 5404R
centrifuge equipped with a swinging bucket rotor. The
resulting cell pellets were resuspended in cold cDMEM,
processed with a chilled Dounce homogenizer, and clari-
fied by centrifugation at 1000 × g for 10 minutes at 4°C.
The supernatant was disrupted using a cup horn sonica-
tor for 4 cycles each composed of 30 seconds at 90%
power, 50% duty cycle followed by 60 seconds on ice.
Aliquots were removed to check sterility and viral titer,
and the remainder aliquoted and frozen at -80°C. The
MAb-1G10 hybridoma was grown in BD Cell Monoclo-
nal Antibody Medium (Fisher). Hybridoma supernatant
was applied to a protein A affinity column (GE Health-
care) and after extensive washes with PBS, the bound
antibody was eluted with 0.1M glycine pH 2.5 and im-
mediately neutralized with 1M Tris-HCl (pH 8.0).
Epitope mapping by randomized peptide phage display
library
Selection of peptides from random peptide phage display
libraries (PhD-C7C and PhD-12; New England Biolabs,
Beverly, MA) was described previously [9]. Briefly,
2 × 1010 phages were incubated with MAb-1G10 mono-
clonal antibody /protein G mixtures for 20 min at roomtemperature. After eight washings with 0.05 M Tris-HCl
buffer (pH 7.5) containing 0.15 M NaCl and 0.05%
Tween 20, the phages were eluted from the complex
with 0.1 M HCl for 8 min at room temperature and neu-
tralized with 1 M Tris-HCl (pH 9.0). The eluted phages
were then amplified in the host strain ER2738 and preci-
pitated with 25% PEG/4 M NaCl. After three additional
rounds of selection of amplified phages, DNA from well-
separated plaques was sequenced, and the corresponding
peptide sequence was then deduced from the DNA
sequence.
Structural analysis
Molecular coordinates for the A33 protein [PDB: 3K7B]
used in structural analysis and modeling were obtained
from the Protein Data Bank [53] then visualized and
analyzed using Pymol (PyMOL Molecular Graphics Sys-
tem, Version 1.1r1, Schrödinger, LLC). To model the
structure of the consensus positive phage display pep-
tide, the structural database was queried using BLAST
for short sequences containing two cysteines separated
by three amino acids (CXXXC). The structures returned
from the search were examined for the presence or ab-
sence of disulphide bonds and for local conformation. If
different the sequence extracted from the database was
altered to the sequence of phage display peptide, energy
minimized using CHARMM [54] and then compared
with the possible locus of the MAb-1G10 epitope.
Protein expression and purification
Briefly, the DNA sequence encoding the residues from
59 to 186 of wild type A33 was amplified by PCR from
vaccinia virus Western Reserve strain [55]. To facilitate
protein purification and refolding, a His tag and peptide
linker were introduced into the N terminal region of the
rA33 construct. Finally, the PCR product was cloned
into pET28 (BD Bioscience). Utilizing this construct as a
template, plasmids encoding A33 containing the desired
mutations were constructed using a kit for site directed
mutagenesis (New England Biolabs) according to manu-
facturer’s instructions using primers described in Table 1.
The accuracy of the resulting constructs was verified by
DNA sequencing. E. coli strain BL21-DE3 was trans-
formed with the resulting plasmids, cultured at 37°C to
an OD600 value of approximately 0.4, and then induced
with 0.2 mM IPTG for 4 hours. Bacteria were collected
by centrifugation for 15 minutes at 5500 × g. The result-
ing cell pellet was washed with PBS, resuspended in
1 mg/mL lysozyme in PBS, incubated at room
temperature for 1 hour, then subjected to sonication on
ice for three cycles of 5 minutes each. Alternatively, bac-
teria were resuspended in 50 mM Tris, 50 mM NaCl,
10 mM EDTA, pH 8.0 and lysed with a French press. In-
clusion bodies were collected by centrifugation at













aAll primers listed in 50-30 direction with the position of the mutation(s) underlined. A common reverse primer was used for all reactions:
AATATATAACAAGAACCCTGGTAATAGAGACCATTACAGCTTTC.
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X-100, solubilized overnight in 6 M guanidine, 20 mM
Tris, 5 mM DTT, pH 8.0 and then incubated with Ni-
NTA agarose beads for 2 hours at room temperature.
The beads were loaded onto a Econo-pac column
(Biorad) and washed with 3 column volumes of 6 M
guanidine. Protein folding was facilitated by washes with
a decreasing concentration of guanidine (6 M, 4 M, 2 M,
1 M), and a final wash with PBS. The refolded proteins
were eluted from the column with 250 mM inidazole in
PBS, pH 8.0 and dialyzed against PBS at 4°C with exten-
sive buffer changes. The protein solution was then clari-
fied by centrifugation at 18000 × g and the resulting
supernatant snap-frozen in liquid nitrogen and stored at
-80°C.
To express and purify soluble recombinant A33 pro-
teins from E.coli, the protein was expressed in BL21
(DE3) at 18°C in the presence of 5% glycerol and 2.5%
ethanol. The soluble fraction containing A33 was
adsorbed onto Talon affinity resin, loaded into an Eco-
Pak column and refolded on the column using the
method described above. Purity of the proteins was
assessed on SDS-PAGE gels (Invitrogen) stained with
GelCode Blue (Pierce) or by HPLC analysis with a Zobax
GF250 size exclusion column.
Peptide synthesis
Synthetic phage peptide mimics RF2-1:ACTSYNEPLC
GGGSAK-(C6-biotin) and RF2-5:ACGDDWPHECGGGS
AK-(C6-biotin) were made by standard 9-fluorenyl-
methoxy carbonyl chemistry and purified by HPLC
(Center for Biologics Evaluation and Research Facility for
Biotechnology Resources, US Food and Drug Adminis-
tration, Rockville, MD). Peptides were confirmed to have
the expected molecular weight by matrix-assisted laser
desorption ionization-time-of-flight mass spectroscopy.Reduced peptides were generated as previously descri-
bed [56]. Briefly, the peptide was dissolved in 0.1 M
phosphate buffer (pH7.0) and incubated with 20 fold
of molar excess of both tris(2-carboxyethyl)phosphine
(TCEP) and N-Ethylmaleimide (NEM) at room tempe-
rature for 2 h. Peptide solutions were stored at -80°C
until use.
ELISAs
96-well polystyrene plates (Corning) were coated with
rA33 proteins (10 μg/ml, 100 μl per well) in PBS over-
night at 4°C, and unbound rA33 was removed with sa-
line containing 0.5% Tween 20 (PBS-T). Non-specific
protein binding was blocked with 5% nonfat dry milk in
PBS-T. Serial dilutions of MAb-1G10 in blocking buffer
were added to wells and incubated for 1 h at 37°C. Wells
were washed 4 times in PBS-T before addition of horse-
radish peroxidase (HRP) -conjugated anti-mouse sec-
ondary antibody (Roche Diagnostics) diluted in blocking
buffer. After 1 h incubation, plates were washed 4 times
prior to application of soluble HRP substrate (BM Blue,
Roche Diagnostics) for 30 min. The reaction was
stopped by adding 1M sulfuric acid, and absorbance at
450 nm was determined using a plate reader (Molecular
Devices). For detection of antibody binding to biotiny-
lated peptides, peptides diluted in phosphate buffer were
added to wells of streptavidin-coated 96-well plates
(Thermo Scientific), plates incubated overnight at 4°C,
and bound antibody detected as described above.
Immunoprecipitation analysis
To prepare antibody-conjugated beads, antibody dilu-
tions were incubated with protein A Dynal magnetic
beads (Invitrogen) according to manufacturer’s instruc-
tions overnight, then treated with excess BS3 crosslinking
agent at room temperature for 30 minutes. Crosslinking
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bound antibody was removed by incubation with 0.1 M
glycine buffer (pH 2.5), followed by three times washing in
PBS-T buffer. 5 μg of each rA33 protein was incubated
with 200 μl of antibody-conjugated beads for 1 hour at
room temperature with consistent rotation. After exten-
sive washing in PBS-T, the bound rA33 proteins were
eluted by using 0.1M glycine (pH 2.5). Eluted proteins
were analyzed by SDS-PAGE and detected by staining
with GelCode Blue (Pierce).
Comet inhibition assay
Confluent monolayers of Vero E6 cells in six-well cell
culture plates (Corning) were infected with the IHD-J
strain of VACV at 50–100 pfu per well in 0.2 mL
cDMEM. One well was left uninfected as a sham con-
trol. After incubation for 1 h at 37°C, the media was
removed, and cells were washed twice with 2 mL PBS.
Virus-only wells received 2mL cDMEM, and virus +
MAb wells received 2 mL cDMEM containing MAb-
1G10 at 12.5 μg/mL. Test wells received 2 mL cDMEM
containing 12.5 μg/mL MAb-1G10 in combination with
concentrations of A33 proteins ranging from 0.1-10
times molar excess over the monoclonal antibody. Some
experiments utilized purified phage instead of A33 pro-
teins. Plates were placed in a CO2 incubator maintained
at 37°C for 46 hours, and comets visualized by staining
the monolayers with 0.13% crystal violet in 5% ethanol/
3% neutral buffered formalin prior to imaging.
Bioinformatics and statistical analysis
Data was obtained from the NIAID Virus Pathogen
Database and Analysis Resource (ViPR) online through
the web site at http://www.viprbrc.org (www.viprbrc.org)
and from the Viral Bioinformatics Resource Center
(VBRC; www.vbrc.org) and was aligned and visualized
using multiple sequence alignment tools available at
these websites. Statistical analysis was performed using
Prism 5 (GraphPad Software). All experiments were per-
formed in duplicate unless otherwise noted.
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